From: Active surveillance study of adverse events following immunisation of children in the Czech Republic
Number of doses | Number of AEFI | Rate (95CI) per 1000 doses | Relative risk (95%CI) | p-value | |
---|---|---|---|---|---|
Age group | |||||
0–11 months | 27555 | 41 | 1.5 (1.1–2.0) | 1 .00 | <0.001* |
1–4 years | 33125 | 35 | 1.1 (0.7–1.5) | 0.71 (0.45–1.12) | |
5–9 years | 12251 | 76 | 6.2 (4.9–7.7) | 4.16 (2.81–6.26) | |
10–14 years | 10620 | 23 | 2.2 (1.4–3.2) | 1.45 (0.83–2.49) | |
Sex | |||||
Boys | 42611 | 94 | 2.2 (1.8–2.7) | 1.05 (0.92–1.21) | 0.515 |
Girls | 40940 | 81 | 2.0 (1.6–2.5) | 1.00 | |
Birth weight | |||||
< 2500 g | 3350 | 7 | 2.1 (0.9–4.1) | 0.48–2.06) | 0.497 |
> 2500 g | 80201 | 168 | 2.1 (1.8–2.4) | 1.00 | |
Education of mother | |||||
Elementary | 10970 | 19 | 1.7 (1.1–2.7) | 1.00 | 0.495* |
Secondary | 46332 | 99 | 2.1 (1.8–2.6) | 1.22 (0.75–2.14) | |
University | 22470 | 48 | 2.1 (1.6–2.8) | 1.22 (0.71–2.22) | |
Not available | 3779 | 9 | 2.4 (1.2–4.4) | 1.38 (0.55–3.19) | |
Education of father | |||||
Elementary | 14277 | 20 | 1.4 ((0.9–2.1) | 1.00 | 0.580* |
Secondary | 41618 | 105 | 2.5 (2.1–3.0) | 1.80 (1.11–3.07) | |
University | 21242 | 39 | 1.8 (1.3–2.5) | 1.31 (0.75–2.37) | |
Not available | 6414 | 15 | 2.3 (1.4–3.9) | 1.67 (0.79–3.43) | |
Place of residence | |||||
Rural | 18214 | 36 | 2.0 (1.4–2.7) | 1.00 | 0.347 |
Urban | 65337 | 139 | 2.1 (1.8–2.5) | 1.02 (0.94–1.10) |